Professor Craig Crews has been awarded the Scheele prize 2021 for his broad excellence in drug discovery and development spanning from molecule to patient. He has combined groundbreaking science with strong entrepreneurship and received wide international recognition for his work on pharmacological modulation of protein turnover. His findings have led to new therapeutic approaches including the development of novel proteasome inhibitors and the PROTAC technology.Read more >
Thanks to the results of his many years of research, Professor Craig M. Crews of Yale University in New Haven, Connecticut, is making innovative new medicines possible. So-called PROTACs (proteolysis-targeting chimeras) activate a cell’s quality control system to target disease-causing proteins for degradation. These new active substances are intended to specifically destroy proteins that, until now, have been therapeutically impervious. For his ground-breaking research, Professor Crews has been awarded the 2020 Heinrich Wieland Prize.
Nature News Feature
Researchers are hijacking the cell’s protein-disposal system in the fight against Alzheimer’s and intractable cancers.
When Craig Crews first managed to make proteins disappear on command with a bizarre new compound, the biochemist says that he considered it a “parlour trick”, a “cute chemical curiosity”.
Today, that cute trick is driving billions of US dollars in investment from pharmaceutical companies such as Roche, Pfizer, Merck, Novartis and GlaxoSmithKline.